A new method for the fast detection of a key antiviral

Journal of Pharmaceutical Analysis publishes method for the fast detection of a key antiviral
Development of novel-nanobody-based lateral-flow Immunochromatographic strip test for rapid detection of recombinant human interferon α2b. Credit: Journal of Pharmaceutical Analysis

Interferons are proteins that constitute an important part of our natural defense systems. These proteins also exhibit a remarkable antiviral activity. The recombinant human interferon α2b (rhIFNα2b) was approved by the U.S. Food and Drug Administration in 1986. It has been used ever since as an antiviral agent for the treatment of hepatitis B and hepatitis C. Despite its widespread applications, however, there remains an issue: the detection of rhIFNα2b is tedious and time-consuming.

Against this backdrop, researchers from China, in a new study, recently developed a novel method for the fast and efficient detection of rhIFNα2b. This paper was made available online on 8 July 2021 and was published in the Journal of Pharmaceutical Analysis on 30 April 2022.

To develop their new method, they immobilized a novel nanobody on a paper strip. The nanobody used in this method was originally derived from an Alpaca—a species of the South American camelid mammal. Subsequently, it was generated in the research laboratory using recombinant DNA technology—a technique used to subclone DNA fragments in order to obtain high quantities of synthetic proteins. This is usually achieved using bacteria or other prokaryotic cells. A nanobody is a functional fragment of a larger antibody. As the immobilized novel nanobody binds rhIFNα2b tightly and with , it was used for a rapid and fool-proof detection of rhIFNα2b.

According to Dr. Junzhi Wang, "Owing to the advantages of nanobodies in reagent preservation, production, and cost, the lateral flow immunochromatography assay using nanobodies has a high potential to replace traditional antibody-based ligand-binding assays for a rapid identification test of recombinant protein therapeutics."

The research team characterized the binding for the I22-rhIFNα2b interaction, i.e. binding between nanobody 122 and rhIFNα2b, using an Octet platform. The obtained data clearly indicated a tight binding. The binding specificity was further validated using Western blotting, a technique used to detect proteins using protein-specific antibodies.

"The rhIFNα2b products currently available in China include injections, injection powders, gels, and pastes. The immunochromatography strips can only be used to evaluate liquids or products in powder form that can be dissolved and applied to the strips. This is because the product needs to diffuse along the strip via ; gels and pastes do not satisfy this requirement," explains Dr. Wang.

Quite interestingly, the developed rhIFNa2b detection assay has a detection limit of 1 µg/mL, which is lower than the existing limits. This makes it a more sensitive lab-based technique for rapid identification of rhIFNα2b. Another big advantage is the use of nanobodies for protein detection. This is because nanobodies can be obtained in an economical manner by harvesting inexpensive bacterial cells. Moreover, large volumes of nanobodies can be obtained with relative ease using routinely used laboratory techniques.

Dr. Wang says, "The operation time of rhIFNα2b identification was shortened from two days to a few minutes with our test. It can, therefore, meet the needs for rapid detection of this family of recombinant products on the market and provide a good foundation for improving the efficiency of market counterfeit detection. In the future, rapid detection could be carried out in an all-round manner."

In summary, the newly developed method could pave the way for smoother, faster, and accurate detection of recombinant or artificially generated proteins, making for early diagnosis and treatment of hepatitis.


Explore further

Nanobody-drug conjugates hijack the human vitamin B12 uptake route

More information: Xi Qin et al, Development of novel-nanobody-based lateral-flow immunochromatographic strip test for rapid detection of recombinant human interferon α2b, Journal of Pharmaceutical Analysis (2021). DOI: 10.1016/j.jpha.2021.07.003
Provided by Cactus Communications
Citation: A new method for the fast detection of a key antiviral (2022, June 9) retrieved 25 June 2022 from https://phys.org/news/2022-06-method-fast-key-antiviral.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
11 shares

Feedback to editors